Cargando…
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of a humanized albumin-binding antibody was fused to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058625/ https://www.ncbi.nlm.nih.gov/pubmed/27532598 http://dx.doi.org/10.1080/19420862.2016.1210747 |
_version_ | 1782459268266459136 |
---|---|
author | Davé, Emma Adams, Ralph Zaccheo, Oliver Carrington, Bruce Compson, Joanne E. Dugdale, Sarah Airey, Michael Malcolm, Sarah Hailu, Hanna Wild, Gavin Turner, Alison Heads, James Sarkar, Kaushik Ventom, Andrew Marshall, Diane Jairaj, Mark Kopotsha, Tim Christodoulou, Louis Zamacona, Miren Lawson, Alastair D. Heywood, Sam Humphreys, David P. |
author_facet | Davé, Emma Adams, Ralph Zaccheo, Oliver Carrington, Bruce Compson, Joanne E. Dugdale, Sarah Airey, Michael Malcolm, Sarah Hailu, Hanna Wild, Gavin Turner, Alison Heads, James Sarkar, Kaushik Ventom, Andrew Marshall, Diane Jairaj, Mark Kopotsha, Tim Christodoulou, Louis Zamacona, Miren Lawson, Alastair D. Heywood, Sam Humphreys, David P. |
author_sort | Davé, Emma |
collection | PubMed |
description | An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of a humanized albumin-binding antibody was fused to the C-termini of Fab constant domains, such that the VL and VH domains were individually connected to the Cκ and CH1 domains by peptide linkers, respectively. The anti-albumin Fv was selected for properties thought to be desirable to ensure a durable serum half-life mediated via FcRn. The Fv domain was further stabilized by an inter-domain disulfide bond. The bispecific format was shown to be thermodynamically and biophysically stable, and retained good affinity and efficacy to both antigens simultaneously. In in vivo studies, the serum half-life of Fab-dsFv, 2.6 d in mice and 7.9 d in cynomolgus monkeys, was equivalent to Fab'-PEG. |
format | Online Article Text |
id | pubmed-5058625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-50586252016-10-24 Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding Davé, Emma Adams, Ralph Zaccheo, Oliver Carrington, Bruce Compson, Joanne E. Dugdale, Sarah Airey, Michael Malcolm, Sarah Hailu, Hanna Wild, Gavin Turner, Alison Heads, James Sarkar, Kaushik Ventom, Andrew Marshall, Diane Jairaj, Mark Kopotsha, Tim Christodoulou, Louis Zamacona, Miren Lawson, Alastair D. Heywood, Sam Humphreys, David P. MAbs Report An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of a humanized albumin-binding antibody was fused to the C-termini of Fab constant domains, such that the VL and VH domains were individually connected to the Cκ and CH1 domains by peptide linkers, respectively. The anti-albumin Fv was selected for properties thought to be desirable to ensure a durable serum half-life mediated via FcRn. The Fv domain was further stabilized by an inter-domain disulfide bond. The bispecific format was shown to be thermodynamically and biophysically stable, and retained good affinity and efficacy to both antigens simultaneously. In in vivo studies, the serum half-life of Fab-dsFv, 2.6 d in mice and 7.9 d in cynomolgus monkeys, was equivalent to Fab'-PEG. Taylor & Francis 2016-08-17 /pmc/articles/PMC5058625/ /pubmed/27532598 http://dx.doi.org/10.1080/19420862.2016.1210747 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Report Davé, Emma Adams, Ralph Zaccheo, Oliver Carrington, Bruce Compson, Joanne E. Dugdale, Sarah Airey, Michael Malcolm, Sarah Hailu, Hanna Wild, Gavin Turner, Alison Heads, James Sarkar, Kaushik Ventom, Andrew Marshall, Diane Jairaj, Mark Kopotsha, Tim Christodoulou, Louis Zamacona, Miren Lawson, Alastair D. Heywood, Sam Humphreys, David P. Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
title | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
title_full | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
title_fullStr | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
title_full_unstemmed | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
title_short | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
title_sort | fab-dsfv: a bispecific antibody format with extended serum half-life through albumin binding |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058625/ https://www.ncbi.nlm.nih.gov/pubmed/27532598 http://dx.doi.org/10.1080/19420862.2016.1210747 |
work_keys_str_mv | AT daveemma fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT adamsralph fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT zaccheooliver fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT carringtonbruce fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT compsonjoannee fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT dugdalesarah fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT aireymichael fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT malcolmsarah fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT hailuhanna fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT wildgavin fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT turneralison fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT headsjames fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT sarkarkaushik fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT ventomandrew fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT marshalldiane fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT jairajmark fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT kopotshatim fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT christodouloulouis fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT zamaconamiren fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT lawsonalastaird fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT heywoodsam fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding AT humphreysdavidp fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding |